How did Gossamer Bio's Q2 2025 revenues and earnings compare to analyst expectations and consensus estimates? | GOSS (Aug 06, 2025) | Candlesense
GOSS

How did Gossamer Bio's Q2 2025 revenues and earnings compare to analyst expectations and consensus estimates?

Based on the excerpt you provided, the release mentions that Gossamer Bio announced its second‑quarter 2025 results and gave a business update, but it does not include any concrete figures for revenue, net income (or loss), earnings per share, or the analyst consensus/expectations for those metrics. Consequently, there is no information in the supplied text that allows us to compare the company’s Q2 2025 revenues or earnings with what Wall Street analysts had projected.

In short: The news snippet you shared does not contain the necessary data (actual Q2 2025 revenue/earnings numbers nor the corresponding analyst consensus estimates), so we cannot assess how Gossamer Bio’s performance stacked up against expectations from the information given. If you have access to the full press release or another source that lists those figures, feel free to share it and I can provide a detailed comparison.

Other Questions About This News

What are the latest enrollment numbers and data readouts from the seralutinib Phase 2/3 clinical trials? What are the potential risks or setbacks mentioned in the business update that could affect the stock? What is the sentiment of institutional investors and analyst rating changes following this announcement? Are there any upcoming catalyst events (e.g., conference presentations, data releases) that could move the stock in the short term? What were the key drivers behind any revenue growth or decline reported in the second quarter? How did the valuation multiples (e.g., P/E, EV/EBITDA) change after the earnings release? What is the current market share outlook for seralutinib versus other PAH/PH-ILD therapies in development? How did the company's cash position and runway change after the quarter, and is additional financing required? Did Gossamer update the timeline for FDA approval or any regulatory milestones for seralutinib? Did Gossamer provide guidance for Q3 and full‑year 2025 earnings, and how does it compare with consensus forecasts? Did the company announce any new partnership or licensing agreements besides the existing Chiesi collaboration?